EUVIMEDEUVIMED entdecken
Crossref

SRS240 - IL-6/JAK/STAT3 signalling promotes ischaemia-reperfusion–induced renal allograft fibrosis

Wenrui Lei, Serena MacMillan, Sarah Hosgood, Michael Nicholson

British Journal of Surgery · 27.03.2026 · 113 (Supplement_2)

DOI: 10.1093/bjs/znag018.224 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Surgery, online erschienen am 27.03.2026. Verfasst von Wenrui Lei und 3 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Renal allograft fibrosis, mainly marked by interstitial fibrosis and tubular atrophy (IF/TA), is a leading cause of late graft failure. Ischaemia–reperfusion injury (IRI) contributes significantly to fibrotic progression, yet underlying molecular mechanisms remain unclear. This study investigates the role of IL-6/JAK/STAT3 signalling in renal graft fibrosis using bulk-RNA sequences analyses and assesses the anti-fibrotic effect of the JAK1/2 inhibitor ruxolitinib.

Methods

Transcriptomic data were analysed from (1) five Gene Expression Omnibus datasets of renal allografts one year post-transplantation (Normal: n = 168; IF/TA: n = 113); and (2) human kidneys after 10 h of ex vivo machine perfusion (EVMP) (n = 9). Gene Ontology, KEGG, and GSEA were used for pathway enrichment. Genes related to IL-6/JAK/STAT3 and other fibrosis markers were selected for further statistical analysis. In vitro, human proximal tubular (TH1) cells were subjected to hypoxia–reoxygenation with or without ruxolitinib, and α-SMA expression were evaluated.

Results

Transcriptomic profiling revealed upregulation of the IL-6/JAK/STAT3 pathway during the transition from acute injury to chronic fibrosis. Notably, JAK1 was elevated after 10 h of EVMP, while JAK2 was predominantly upregulated in chronic graft fibrosis samples. Early and sustained activation of fibroblast markers and various pro-fibrotic genes was observed. In vitro, ruxolitinib significantly downregulated α-SMA expression in TH1 cells after reoxygenation.

Conclusions

IL-6/JAK/STAT3 signalling is an important mediator of IRI-induced renal graft fibrosis. JAK1/2 inhibition may offer a promising therapeutic approach to mitigate chronic graft deterioration.

Zitieren

APA

Lei, W., MacMillan, S., Hosgood, S., & Nicholson, M. (2026). SRS240 - IL-6/JAK/STAT3 signalling promotes ischaemia-reperfusion–induced renal allograft fibrosis. British Journal of Surgery, 113(Supplement_2). https://doi.org/10.1093/bjs/znag018.224

Vancouver

Lei W, MacMillan S, Hosgood S, Nicholson M. SRS240 - IL-6/JAK/STAT3 signalling promotes ischaemia-reperfusion–induced renal allograft fibrosis. British Journal of Surgery. 2026;113(Supplement_2). doi:10.1093/bjs/znag018.224

BibTeX
@article{Lei2026,
  author = {Lei, Wenrui and MacMillan, Serena and Hosgood, Sarah and Nicholson, Michael},
  title = {SRS240 - IL-6/JAK/STAT3 signalling promotes ischaemia-reperfusion–induced renal allograft fibrosis},
  journal = {British Journal of Surgery},
  year = {2026},
  volume = {113},
  number = {Supplement_2},
  doi = {10.1093/bjs/znag018.224}
}
Kostenlos starten →